Efficacy and tolerance of vinorelbine and fluorouracil combination as first-line chemotherapy of advanced breast cancer: results of a phase II study using a sequential group method

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
V DierasM Marty

Abstract

To assess the antitumor efficacy and safety profile of the combination of Fluorouracil (5FU) and vinorelbine given as first-line therapy to patients with advanced breast cancer. As defined in the seven consecutive steps of a phase II group sequential design, 63 patients received 5FU 750 mg/m2/d for 5 consecutive days as a continuous infusion and vinorelbine 30 mg/ m2 on days 1 and 5 as a short intravenous (I/V) infusion every 3 weeks. Forty-one of 63 patients achieved an objective response, which allowed us to discontinue the study and reject a response rate less than 50% with a statistical power of 90%. The unbiased estimate of the response rate was 61.6%. Response rate did not differ significantly according to the following: (1) type of prior adjuvant therapy (none, n = 23; without anthracycline, n = 6; with anthracyline, n = 34); (2) site of metastatic disease; and (3) number of metastatic sites. The median time to progression was 8.4 months. The median response duration was 12.3 months, and the median duration of complete response (CR), from the first assessment of CR, was 7.3 months. The median overall survival time was 23 months (28.1 months for patients with a CR). The main toxicities (grades 3 and 4) were neutropenia (9...Continue Reading

Citations

Sep 24, 2005·Fundamental & Clinical Pharmacology·Véronique Sébille, Eric Bellissant
Dec 24, 2005·Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·José Luis González VelaJuan Francisco González Guerrero
Aug 25, 2007·Cancer Chemotherapy and Pharmacology·Marwan GhosnUNKNOWN Cancer Research Group/Collaborative Group (CRG/CG), Beirut-Lebanon
Oct 22, 2008·Expert Opinion on Pharmacotherapy·Jacques Bonneterre, Nicolas Penel
Oct 3, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A BerrutiL Dogliotti
Apr 19, 2002·Chronobiology International·B Coudert
Apr 18, 2001·The Oncologist·F J EstevaG N Hortobagyi
Aug 31, 2000·Breast Cancer Research and Treatment·A ZambelliG Robustelli della Cuna
Nov 25, 2017·The Hastings Center Report·Laura E Bothwell, Aaron S Kesselheim
May 16, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·L ZelekM Spielmann
Dec 12, 2001·Critical Reviews in Oncology/hematology·M S AaproJ B Vermorken
Nov 24, 2005·Annals of Oncology : Official Journal of the European Society for Medical Oncology·F NolèA Goldhirsch

❮ Previous
Next ❯

Related Concepts

Related Feeds

Breast Invasive Carcinoma

Invasive breast cancers indicate a spread into breast tissues and lymph nodes. Here are the latest discoveries pertaining to breast invasive carcinomas.

Breast Invasive Carcinoma (Keystone)

Invasive breast cancers indicate a spread into breast tissues and lymph nodes. Here are the latest discoveries pertaining to breast invasive carcinomas.

Related Papers

Annals of Oncology : Official Journal of the European Society for Medical Oncology
M VassilomanolakisA P Efremidis
Annals of Oncology : Official Journal of the European Society for Medical Oncology
G MustacchiC Dellach
Gan to kagaku ryoho. Cancer & chemotherapy
Vicharn LorvidhayaAnun Tonusin
© 2021 Meta ULC. All rights reserved